MK-7264

MK-7264 · Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for MK-7264, covering 2017-01-12 to 2020-10-22. Get the full timeline:

Most recent: Clinical Trial Update: A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) [Phase 2]